<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363321</url>
  </required_header>
  <id_info>
    <org_study_id>B7841003</org_study_id>
    <secondary_id>2017-001255-31</secondary_id>
    <nct_id>NCT03363321</nct_id>
  </id_info>
  <brief_title>PF-06741086 Long-term Treatment in Severe Hemophilia</brief_title>
  <official_title>A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and efficacy of long-term
      treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month
      Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">August 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 393</time_frame>
    <description>Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Following parameters were analyzed for laboratory examination: hematology, serum chemistry, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with changes from baseline in vital signs</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Following parameters were analyzed for vital sign examination: blood pressure, pulse rate, temperature, respiration rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Following parameters were analyzed for ECG examinations: QT interval (QTc), QTcF interval (Fridericia's Correction), QRS complex, PR interval, and RR interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Following parameters were analyzed for injection site reaction examinations: induration, erythema, edema, rash, pruritus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subejct with infusion site reactions</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Following parameters were analyzed for infusion site reactions: induration, erythema, edema, rash, pruritus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Bleeding episodes requiring treatment with factor replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatments for breakthrough bleeding episodes</measure>
    <time_frame>Day 1 to Day 393</time_frame>
    <description>Treatments with factor replacement.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hemophilia A or B</condition>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 subcutaneous injection</description>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 5)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A or B (Factor VIII or Factor IX activity â‰¤ 1%)

          -  Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive
             inhibitor test result (above the upper limit of normal) at the local laboratory and
             must receive a bypass agent as primary treatment for bleeding episodes.

          -  Episodic (on-demand) treatment regimen prior to screening

          -  At least 6 acute bleeding episodes during the 6-month period prior to screening

        Exclusion Criteria:

          -  Known coronary artery, thrombotic, or ischemic disease

          -  Concomitant treatment with activated prothrombin complex concentrate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Denver Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <state>Puente ALTO</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apteka Szpitalna UCK</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phoenix Pharma (Pty) Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern CAPE</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2913</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitatsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7841003</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

